Download PDF
Klin Monbl Augenheilkd 2023; 240(07): 891-896
DOI: 10.1055/a-2029-0163
Klinische Studie

Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon-α2b: A Survey of Tertiary Eye Centres in Germany

Gegenwärtige Vorgehensweise bei der Behandlung von epithelialen und melanozytären Tumoren mit Interferon-α2b: eine Umfrage unter tertiären Augenzentren in Deutschland
Jana Jiang
1   Eye Center, University Medical Center Freiburg, Germany
,
Daniel Böhringer
1   Eye Center, University Medical Center Freiburg, Germany
,
Claudia Auw-Hädrich 
1   Eye Center, University Medical Center Freiburg, Germany
,
Philip Christian Maier
1   Eye Center, University Medical Center Freiburg, Germany
,
Teresa Barth
2   Department of Ophthalmology, University Hospital Regensburg, Germany
,
Nicole Eter
3   Department of Ophthalmology, University of Münster Medical Center, Germany
,
Matthias Fuest
4   Department of Ophthalmology, RWTH Aachen University, Germany
,
Gerd Geerling
5   Department of Ophthalmology, University Hospital, University of Düsseldorf, Germany
,
Ludwig M. Heindl
6   Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Germany
,
Martina Herwig-Carl
7   Department of Ophthalmology, University of Bonn, Germany
,
Christoph Hintschich
8   Department of Oculoplastic and Orbital Service, Munich University Eye Hospital, Germany
,
Katerina Hufendiek
9   University Eye Hospital, Hannover Medical School, Germany
,
Daniel Kampik
10   Department of Ophthalmology, University Hospital of Würzburg, Germany
,
Wolfgang Lieb
11   Department of Ophthalmology, St. Vincentius Clinic Karlsruhe, Germany
,
Daniel Meller
12   Department of Ophthalmology, Jena University Hospital, Germany
,
Arthur Mueller
13   Department of Ophthalmology, University Hospital Augsburg, Germany
,
Norbert Pfeiffer
14   Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Germany
,
Matus Rehak
15   Department of Ophthalmology, Eye Clinic, Justus-Liebig-University Giessen, University Hospital Giessen and Marburg GmbH, Germany
,
Marc Schargus
16   Department of Ophthalmology, Asklepios Hospital Nord-Heidberg, Hamburg, Germany
,
Berthold Seitz 
17   Department of Ophthalmology, Saarland University Medical Center, Homburg, Germany
,
Martin Spitzer
18   Clinic for Ophthalmology, University Medical Center Hamburg-Eppendorf (UKE), Germany
,
Andreas Stahl
19   Department of Ophthalmology, University Medicine Greifswald, Germany
,
Daniela Süsskind
20   Department of Ophthalmology, Eberhard Karls Universität, Tübingen, Germany
,
Christian van Oterendorp
21   Department of Ophthalmology, Georg-August University, Göttingen, Germany
,
Felix Mathias Wagner
22   Ophthalmology Department, Philipps University of Marburg, Germany
,
Henrike Westekemper
23   Department of Ophthalmology, University Hospital Essen, Germany
,
Focke Ziemssen
24   Department of Ophthalmology, University Hospital Leipzig, Germany
,
Thomas Reinhard
1   Eye Center, University Medical Center Freiburg, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Purpose To evaluate the standard of care, in particular the use of topical or subconjunctival interferon-α2b, in treating ocular surface squamous neoplasia or melanocytic tumours in tertiary eye centres in Germany.

Methods A survey containing 14 questions was sent to 43 tertiary eye centres in Germany. The questions addressed the surgical and medical management of ocular surface squamous neoplasia and melanocytic tumours (primary acquired melanosis and malignant melanoma), as well as the clinical experiences and difficulties in prescribing off-label interferon-α2b eye drops and subconjunctival injections.

Results Twenty-four tertiary eye centres responded to the survey. Eighty-three percent of centres had used interferon-α2b in their clinical practice and 25% prescribed it as the first-line cytostatic agent following surgical excision of ocular surface squamous neoplasia, while 10% would do so for melanocytic tumours. Correspondingly, the majority of respondents selected mitomycin C as their first-line agent. Side effects were uncommon with topical interferon-α2b eye drops but were more frequently reported after subconjunctival interferon-α2b injections. In total, eight centres had experience with interferon-α2b injections. The most significant obstacles perceived by ophthalmologists when prescribing interferon-α2b were its high cost and the reimbursement thereof.

Conclusion Off-label mitomycin C was the preferred adjuvant therapy for epithelial and melanocytic tumours, with interferon-α2b being the standard second-line option. Interferon-α2b has predominantly been used to treat ocular surface squamous neoplasia and, to a lesser extent, melanocytic tumours at German tertiary eye centres. Following its market withdrawal, supply shortages of interferon-α2b are likely to have a profound impact on patient care and their quality of life.

Zusammenfassung

Ziel Evaluation des Therapiestandards, insbesondere der Verwendung von topischem oder subkonjunktivalem Interferon-α2b, bei der Behandlung von Neoplasien der plattenepithelialen, okulären Oberfläche oder melanozytären Tumoren der Augenoberfläche in tertiären Augenzentren in Deutschland.

Methoden Eine Umfrage mit 14 Fragen wurde an 43 tertiäre Augenzentren in Deutschland verschickt. Die Fragen befassten sich mit der chirurgischen und medizinischen Behandlung von Neoplasien der plattenepithelialen, okulären Oberfläche und melanozytären Tumoren (primär erworbene Melanose und malignes Melanom) sowie den klinischen Erfahrungen und Schwierigkeiten bei der Verschreibung von Off-Label Interferon-α2b-Augentropfen und subkonjunktivalen Injektionen.

Ergebnisse 24 tertiäre Augenzentren nahmen an der Umfrage teil. 83% der Zentren hatten Interferon-α2b eingesetzt und 25% verschrieben es als First-Line-Therapie nach chirurgischer Entfernung von Neoplasien der plattenepithelialen, okulären Oberfläche, wohingegen 10% dies bei melanozytären Tumoren angewendet hätten. Dementsprechend wählte die Mehrheit der Befragten Mitomycin C als Mittel der ersten Wahl aus. Nebenwirkungen waren bei topischen Interferon-α2b-Augentropfen selten, wurden aber häufiger nach subkonjunktivalen Interferon-α2b-Injektionen gemeldet. Insgesamt hatten 8 Zentren Erfahrungen mit Interferon-α2b-Injektionen. Die größten Hürden, die Augenärzte bei der Verschreibung von Interferon-α2b hinderten waren die hohen Kosten und deren Übernahme durch die Krankenkassen.

Schlussfolgerung Off-Label Mitomycin C war die bevorzugte adjuvante Therapie für epitheliale und melanozytäre Tumoren, während Interferon-α2b Standardoption für eine Zweitlinientherapie war. Interferon-α2b wurde in deutschen, tertiären Augenzentren vorwiegend zur Behandlung von Neoplasien der plattenepithelialen, okulären Oberfläche und in geringerem Maße von melanozytären Tumoren eingesetzt. Nach der Marktrücknahme von Interferon-α2b werden Lieferengpässe wahrscheinlich beträchtliche Auswirkungen auf die Patientenversorgung und ihre Lebensqualität haben.

Key messages

What is already known

  • Off-label IFN-α2b was used to treat ocular surface tumours (neo)adjuvantly for many years with good efficacy and few side effects. However, it was withdrawn from the market in 2019.

  • Little is known about the use of IFN-α2b to treat patients with melanocytic tumours or OSSN in Germany.

What this study shows

  • Among tertiary eye centres in Germany, 25% of respondents prescribed IFN-α2b as the first-line cytostatic agent following surgical excision of OSSN, while 10% would do so for melanocytic tumours.

  • The most significant obstacles to prescribing IFN-α2b were its high cost and the reimbursement thereof.

Key words

5-fluorouracil - mitomycin C - interferon-α2b - ocular surface squamous neoplasia - conjunctival melanoma

Schlüsselwörter

5-Fluorouracil - Mitomycin C - Interferon-α2b - Bindehautmelanom - Neoplasie der plattenepithelialen, okulären Oberfläche

Supporting Information



Publication History

Received: 22 December 2022

Accepted: 06 February 2023

Accepted Manuscript online:
06 February 2023

Article published online:
05 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Honavar SG, Manjandavida FP. Tumors of the ocular surface: A review. Indian J Ophthalmol 2015; 63: 187-203
    CrossrefPubMedSearch in Google Scholar
  • 2 Auw-Hädrich C, Reinhard T. Conjunctival malignancies. Ophthalmologe 2019; 116: 989-1004
    CrossrefPubMedSearch in Google Scholar
  • 3 Glossmann JP, Skoetz N, Starbatty B. et al. [Conjunctival melanoma: Standard operating procedures in diagnosis, treatment and follow-up care]. Ophthalmologe 2018; 115: 489-498
    CrossrefPubMedSearch in Google Scholar
  • 4 Auw-Hädrich C, Bredow L, Reinhard T. Bindehautdegenerationen und -neoplasien. Klin Monbl Augenheilkd 2013; 230: 445-463
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Surv Ophthalmol 2004; 49: 3-24
    CrossrefPubMedSearch in Google Scholar
  • 6 Midena E, Frizziero L, Parrozzani R. Pharmacotherapy and Immunotherapy of Conjunctival Tumors. Asia Pac J Ophthalmol (Phila) 2017; 6: 121-131
    CrossrefPubMedSearch in Google Scholar
  • 7 Kusumesh R, Ambastha A, Kumar S. et al. Retrospective Comparative Study of Topical Interferon alpha2b Versus Mitomycin C for Primary Ocular Surface Squamous Neoplasia. Cornea 2017; 36: 327-331
    CrossrefPubMedSearch in Google Scholar
  • 8 Venkateswaran N, Mercado C, Galor A. et al. Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia. Am J Ophthalmol 2019; 199: 216-222
    CrossrefPubMedSearch in Google Scholar
  • 9 Galor A, Karp CL, Chhabra S. et al. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol 2010; 94: 551-554
    CrossrefPubMedSearch in Google Scholar
  • 10 Shields CL, Kaliki S, Kim HJ. et al. Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification. Cornea 2013; 32: 248-256
    CrossrefPubMedSearch in Google Scholar
  • 11 Shah SU, Kaliki S, Kim HJ. et al. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification. Arch Ophthalmol 2012; 130: 159-164
    CrossrefPubMedSearch in Google Scholar
  • 12 Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol 2008; 145: 124-129
    CrossrefPubMedSearch in Google Scholar
  • 13 Herold TR, Hintschich C. Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol 2010; 248: 111-115
    CrossrefPubMedSearch in Google Scholar
  • 14 Garip A, Schaumberger MM, Wolf A. et al. Evaluation of a short-term topical interferon alpha-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia. Orbit 2016; 35: 29-34
    CrossrefPubMedSearch in Google Scholar
  • 15 Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984; 2: 336-352
    CrossrefPubMedSearch in Google Scholar
  • 16 González-Navajas JM, Lee J, David M. et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12: 125-135
    CrossrefPubMedSearch in Google Scholar
  • 17 Adler E, Turner JR, Stone DU. Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012. Cornea 2013; 32: 1558-1561
    CrossrefPubMedSearch in Google Scholar
  • 18 Nanji AA, Moon CS, Galor A. et al. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. Ophthalmology 2014; 121: 994-1000
    CrossrefPubMedSearch in Google Scholar
  • 19 Karp CL, Galor A, Chhabra S. et al. Subconjunctival/perilesional recombinant interferon alpha2b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology 2010; 117: 2241-2246
    CrossrefPubMedSearch in Google Scholar
  • 20 Al Bayyat G, Arreaza-Kaufman D, Venkateswaran N. et al. Update on pharmacotherapy for ocular surface squamous neoplasia. Eye Vis (Lond) 2019; 6: 24
    CrossrefPubMedSearch in Google Scholar
  • 21 Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol 2013; 24: 336-342
    CrossrefPubMedSearch in Google Scholar
  • 22 Höllhumer R, Williams S, Michelow P. Ocular surface squamous neoplasia: management and outcomes. Eye (Lond) 2021; 35: 1562-1573
    CrossrefPubMedSearch in Google Scholar
  • 23 Kempin R, Tost F. [Topical chemotherapy for conjunctival tumours – the medical and legal bearings of the case]. Klin Monbl Augenheilkd 2014; 231: 594-602
    Thieme ConnectPubMedSearch in Google Scholar